Before its recent Phase 3 LSD win, Definium modeled up to ...

Definium Therapeutics announced positive Phase 3 trial results for DT120, an oral LSD treatment for generalized anxiety disorder and major depressive disorder, and modeled potential annual pricing between $28,000 and $70,000 per patient, referencing Spravato's pricing. The company must now convince regulators and payers of the treatment's value given the intensive monitoring requirements and novel therapy approach.

This Wire brief sits within Fusion42's coverage of Health.